Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

BACKGROUND: Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP). METHODS: Ipilimumab was available upon physician request for patients aged 16 or over with pretreated sta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ascierto, Paolo A, Simeone, Ester, Sileni, Vanna Chiarion, Pigozzo, Jacopo, Maio, Michele, Altomonte, Maresa, Del Vecchio, Michele, Di Guardo, Lorenza, Marchetti, Paolo, Ridolfi, Ruggero, Cognetti, Francesco, Testori, Alessandro, Bernengo, Maria Grazia, Guida, Michele, Marconcini, Riccardo, Mandalà, Mario, Cimminiello, Carolina, Rinaldi, Gaetana, Aglietta, Massimo, Queirolo, Paola
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4030525/
https://ncbi.nlm.nih.gov/pubmed/24885479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-12-116
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares